Country Access Report
Canada has limited medical access rather than general psychedelic medicine approval. Spravato is marketed, racemic ketamine is authorised as an anaesthetic and used off-label in some psychiatric and pain settings, and psilocybin or MDMA access remains exceptional through clinical trials, the Special Access Programme and related CDSA exemptions. Public reimbursement is limited: CDA-AMC recommended that esketamine not be reimbursed, BC PharmaCare treated Spravato as non-benefit, and Ontario/WSIB materials show only narrow formulary handling for ketamine and esketamine rather than broad public coverage.
Read the access level as a starting point, then check the compound notes below. The practical question is whether a patient can move through a real pathway today, or whether access still depends on a trial, exception route, private-care model, or future reimbursement decision.
Look for approved use, named specialist settings, eligibility rules, and whether care is routine or exceptional.
Separate clinical trials, special access, compassionate use, and unlicensed-medicine routes from routine medical availability.
Check who pays, where care can happen, and whether trained teams, product supply, and site governance are in place.
These notes separate what is available today from research, exceptional-access, private-care, and payment routes. When the guide has not verified a pathway, the compound stays marked as incomplete rather than treated as unavailable.
Compound Access
Psilocybin has no approved therapeutic product in Canada. Health Canada says clinical trials are the preferred route for unapproved psilocybin research, while the SAP and CDSA exemptions can support narrow patient-specific access in serious cases. SAP authorisation is not market approval and should not be assumed to be reimbursed. [1] [2] [3]
Compound Access
MDMA is controlled under Schedule I of the CDSA and has no approved therapeutic product in Canada. Health Canada's SAP notice covers possible psilocybin and MDMA authorisations for psychedelic-assisted psychotherapy, but those decisions are case-by-case and patients cannot possess or transport restricted drugs under the class exemption. [1] [2] [3]
Compound Access
Spravato is marketed in Canada and appears in Health Canada's Drug Product Database as a nasal esketamine product. The current Canadian reimbursement picture remains constrained: CDA-AMC recommended do not reimburse, BC PharmaCare treated Spravato as non-benefit, and WSIB materials describe narrow formulary criteria while noting that Ontario Drug Benefit does not cover ketamine HCl or esketamine nasal spray. [1] [2] [3] [4] [5]
Compound Access
Ketamine is controlled under Schedule I but has legitimate medical uses as an anaesthetic. Health Canada has cautioned that off-label psychiatric use, including compounded formulations, has not been assessed by the regulator for safety and benefit. Reimbursement depends on setting and payer; it should not be described as a nationally reimbursed psychiatric pathway. [1] [2] [3]
Compound Access
Compound Access
No authorised Canadian medicine or reimbursed treatment pathway for 5-MeO-DMT was verified in the reviewed sources. Because Canadian controlled-status questions can depend on exact substance identity, any clinical or commercial access claim should be checked against the CDSA and Health Canada before publication. [1] [2]
Compound Access
Compound Access
Compound Access
Compound Access
Last updated 9 May 2026. Source links come from the medical access guide.